The Motley Fool · Jan 29, 2024
Is Invitae Stock a Buy Now?
Invitae shares have lost more than 80% over the past year and a half.
NV
NYSE · NVTA
Invitae Corporation
Healthcare · Medical - Diagnostics & Research
$0.02
Down-$0.01 (-35.59%)
Updated Aug 15, 2026, 4:02 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 5.44M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 22.46M
- Avg. volume
- 12.85M
Price performance
NVTA price history
1M range · 0 trading sessions · Daily adjusted prices
NVTA does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest NVTA news
The latest Smart Investors Daily articles mentioning NVTA.
Stock researchCompany · Overview
NVTA research
Overview
Company profile and research snapshot.
Company profile
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 13, 2023 | Piper Sandler | Underweight | — |
| Oct 23, 2023 | Goldman Sachs | Sell | — |
| Oct 20, 2023 | Goldman Sachs | Sell | — |
| Aug 15, 2023 | Piper Sandler | Underweight | — |
| Jul 24, 2023 | Goldman Sachs | Sell | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Dec 22, 2023
Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock
Invitae (NVTA) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks Investment Research · Dec 13, 2023
What Makes Invitae (NVTA) a New Buy Stock
Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The Motley Fool · Dec 5, 2023
Better Growth Stock: CRISPR Therapeutics vs. Invitae
One of these stocks may be riskier than the other...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
